Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Maze Therapeutics, Inc.NASDAQ: MAZE
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $93K (cash outflow) fell 68.9% year over year, behind the -49.6% change in trailing-twelve-month capital expenditures. Sequentially, it rose 173.5% from the prior quarter. Over 3 fiscal years it compounded at -26.1% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -68.9% toward the trailing-twelve-month pace of -49.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (794K) USD
- Year-over-year change
- +30.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (794K) | +30.8% |
| FY2024 | 2024-12-31 | (1.15M) | -160.1% |
| FY2023 | 2023-12-31 | (441K) | +77.6% |
| FY2022 | 2022-12-31 | (1.97M) | — |
Capital Expenditures vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -49.6% is the 7th highest of 8, against a peer median of -3.8%.
- Capital expenditures amounts to 2.9% of revenue for MAZE, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $302.05M USD | +1172.9% | +25.3% | 29.9% | |
| LTM Sep 2026 | $18.86M USD | -13.1% | +27.0% | 2.9% | |
| LTM Mar 2026 | $1.24M USD | +4.2% | +200.5% | 0.3% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.02M USD | -3.8% | -26.2% | 1.1% |
| LTM Mar 2026 | $588K USD | -49.6% | -26.1% | 2.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $319K USD | -59.7% | +91.1% | 3.1% |
| FY2025 | €237.26K EUR | -28.8% | -24.9% | 5.3% | |
| LTM Mar 2026 | $36.19K USD | +29.2% | -21.0% | — | |
| Peer median (excluding MAZE) | — | -3.8% | +25.3% | 3.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.